Relmada Therapeutics Inc
F:4E2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Relmada Therapeutics Inc
F:4E2
|
US |
|
J
|
Jones Lang LaSalle Inc
F:4J2
|
US |
|
Glencore PLC
LSE:GLEN
|
CH |
Multiples-Based Value
The Multiples-Based Value for
Relmada Therapeutics Inc (4E2) under the Base Case is 0.28 EUR.
Compared with the current market price of 3.82 EUR, the stock appears
Overvalued by 93% .
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.